Literature DB >> 32385771

PlGF silencing combined with PEDF overexpression: Modeling RPE secretion as potential therapy for retinal neovascularization.

Rute S Araújo1,2, Gabriela A Silva3,4.   

Abstract

Ocular neovascularization is a defining feature of several blinding diseases. We have previously described the effectiveness of long-term pigment epithelium-derived factor (PEDF) expression in the retina of diabetic mice in ameliorating some diabetic retinopathy hallmarks. In this study, we aimed to investigate if the antiangiogenic potential of PEDF overexpression was enhanced in combination with placental growth factor (PlGF) silencing. Human RPE cells were transfected with a self-replicating episomal vector (pEPito) for PEDF overexpression and/or a siRNA targeting PlGF gene. Conditioned media from PEDF overexpression, from PlGF inhibition and from their combination thereof were used to culture human umbilical vein endothelial cells, and their proliferation rate, migration capacity, apoptosis and ability to form tube-like structures were analyzed in vitro. We here demonstrate that pEPito-driven PEDF overexpression in combination with PlGF silencing in RPE cells does not affect their viability and results in an enhanced antiangiogenic activity in vitro. We observed a significant decrease in the migration and proliferation of endothelial cells, and an increase in apoptosis induction as well as a significant inhibitory effect on tube formation. Our findings demonstrate that simultaneous PEDF overexpression and PlGF silencing strongly impairs angiogenesis compared with the single approaches, providing a rationale for combining these therapies as a new treatment for retinal neovascularization.

Entities:  

Keywords:  Angiogenesis; Pigment epithelium-derived factor (PEDF); Placental growth factor (PlGF); Retinal neovascularization; Retinal pigment epithelium (RPE)

Mesh:

Substances:

Year:  2020        PMID: 32385771     DOI: 10.1007/s11033-020-05496-2

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  41 in total

Review 1.  Targeting VEGF in eye neovascularization: What's new?: A comprehensive review on current therapies and oligonucleotide-based interventions under development.

Authors:  Marialaura Amadio; Stefano Govoni; Alessia Pascale
Journal:  Pharmacol Res       Date:  2015-12-08       Impact factor: 7.658

Review 2.  Retinal angiogenesis in development and disease.

Authors:  Ray F Gariano; Thomas W Gardner
Journal:  Nature       Date:  2005-12-15       Impact factor: 49.962

3.  Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.

Authors:  P Carmeliet; L Moons; A Luttun; V Vincenti; V Compernolle; M De Mol; Y Wu; F Bono; L Devy; H Beck; D Scholz; T Acker; T DiPalma; M Dewerchin; A Noel; I Stalmans; A Barra; S Blacher; T VandenDriessche; A Ponten; U Eriksson; K H Plate; J M Foidart; W Schaper; D S Charnock-Jones; D J Hicklin; J M Herbert; D Collen; M G Persico
Journal:  Nat Med       Date:  2001-05       Impact factor: 53.440

4.  Increased expression of placenta growth factor in proliferative diabetic retinopathy.

Authors:  A Khaliq; D Foreman; A Ahmed; H Weich; Z Gregor; D McLeod; M Boulton
Journal:  Lab Invest       Date:  1998-01       Impact factor: 5.662

5.  Basement membrane and growth factor gene expression in normal and diabetic human retinas.

Authors:  K S Spirin; M Saghizadeh; S L Lewin; L Zardi; M C Kenney; A V Ljubimov
Journal:  Curr Eye Res       Date:  1999-06       Impact factor: 2.424

Review 6.  Ocular neovascularization.

Authors:  Peter A Campochiaro
Journal:  J Mol Med (Berl)       Date:  2013-01-18       Impact factor: 4.599

Review 7.  A review of anti-VEGF agents for proliferative diabetic retinopathy.

Authors:  P Osaadon; X J Fagan; T Lifshitz; J Levy
Journal:  Eye (Lond)       Date:  2014-02-14       Impact factor: 3.775

8.  Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR).

Authors:  Stanislao Rizzo; Federica Genovesi-Ebert; Emanuele Di Bartolo; Andrea Vento; Sofia Miniaci; George Williams
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-02-20       Impact factor: 3.117

9.  Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.

Authors:  Helen A Mintz-Hittner; Ronald R Kuffel
Journal:  Retina       Date:  2008-06       Impact factor: 4.256

Review 10.  Review of anti-VEGF therapy in proliferative diabetic retinopathy.

Authors:  Maria Stephanie R Jardeleza; Joan W Miller
Journal:  Semin Ophthalmol       Date:  2009 Mar-Apr       Impact factor: 1.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.